http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비글개에서 인체 재조합 적혈구 조혈인자, rHuEPO의 아만성 정맥독성에 관한 연구
조명행,성하정,김형식,곽승준,천선아,한하수,임소영,안미영,김원배,김병문,안병옥,홍성렬,이병무 성균관대학교 약학연구소 1998 成均藥硏論文集 Vol.10 No.1
The subchronic toxicity study of rHuEPO, a newly developed recombinant erythropoietin, was investigated for 13 weeks in Beagle dogs intravenously treated with doses of 100,500 and 2,500 IU/㎏/day. There were no significant changes in body weight, food intake, physical and opthalmic examination, urine analysis, etc. Any toxic response was not observed except for enlarged spleen and extramedullary hematopoiesis. These results indicate that the no-observed adverse effect level (NOAEL) of rHuEPO is 100 IU/㎏ in Beagle dogs.
승온열탈착에 의한 Ni-CaO 촉매에서의 아세톤의 흡착특성 분석
고병열,이호인,홍성진,조규호 한국공업화학회 1998 응용화학 Vol.2 No.2
Acetone adsorption on the Ni-CaO catalyst has been investigated using temperature-programmed desorption technique under ultra-high vacuum condition. Acetone adsorbed on the 2 wt%Ni-CaO catalyst decomposes mainly to carbon monoxide and hydrogen at 380℃, 590℃ and 790℃ simultaneously. With the increase of Ni loading, the acetone decomposition temperature shifts to higher temperature region suggesting that the catalyst basicity change due to Ni addition causes the weaker interaction between acetone and Ni-CaO than in case of pure CaO. So we could suggest that the added Ni decreases the Ni-CaO catalyst basicity to make the internal acetone bond strong resulting in less dissociation of acetone to hydrogen.
C7- 이환체 구조를 갖는 새로운 플루오로퀴놀론계 항생물질의 흰쥐 체내동태와 조직분포
조재열(Jae Youl Cho),한승희(Seung Hee Han),김병오(Byoung O Kim),남권호(Kweon Ho Nam),손호정(Ho Jung Son),이재욱(Jae Wook Lee),유영효(Young Hyo Yu),박명환(Myung Hwan Park) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.3
The pharmacokinetics of DWP20364 (1-cyclopropyl-5-amino-6,8-difluoro-7-(2,7-diazabicyclo[3,3,0] oct-4-ene-7-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid), a novel fluoroquinolone containing C7-bicyclic structure, were compared with those of ciprofloxacin (CPFX) after single intravenous (i.v.) and oral (p.o.) administration to rats using microbiological assay (bioassay). After i.v. administration to rats, the plasma concentrations of the two drugs declined biexponentially. The terminal half-lives (t_(½β)) of DWP20364 were 110±13.2 min and 117±3.09 min after i.v. and p.o. administration, respectively, and they were significantly higher than those of CPFX (45.5±9.52 min and 48.3±12.1 min, respectively). Similar results were also obtained from plasma concentrations and area under the plasma concentration-time curves. The total body clearance of DWP20364, 7.82±0.37 ml/min/kg was significantly slower than that of CPFX, 27.3±11.1 ml/ min/kg. Above data suggested that the antimicrobial activity of DWP20364 could be lnger than that of CPFX. The urinary recovery after i.v. and p.o. administration of DWP20364 was signifcantly lower than those of CPFX suggesting that the effect of DWP20364 on urinary tract infection could be lower than that of CPFX. The serum protein binding values of DWP20364 at 2 ㎍/ml were apparently 91.5∼93.1% in rats and human. DWP20364 was distributed by the order of liver, lung, kidney, spleen, heart, muscle and brain collected at 30 min after orally administered.
( Jeong-Yup Kim ),( Young-Youl Hyun ),( Ji-Eun Lee ),( Hye-Ran Yoon ),( Gu-Hwan Kim ),( Han-Wook Yoo ),( Seong-Tae Cho ),( No-Won Chun ),( Byoung-Chunn Jeoung ),( Hwa-Jung Kim ),( Keong-Wook Kim ),( S 대한내과학회 2010 The Korean Journal of Internal Medicine Vol.25 No.4
Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α-GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease. (Korean J Intern Med 2010;25:415-421)
메타데이타의 생성 및 관리를 위한 RDF 문서 검증기와 N-Triple 생성기
조성훈,송병열,조현규,최의인,Cho, Sung-Hoon,Song, Byoung-Youl,Cho, Hyun-Gyu,Choi, Eui-In 한국정보처리학회 2004 정보처리학회논문지B Vol.11 No.5
전자상거래가 활성화됨에 따라 웹 상에서 공유되는 기업 정보와 카탈로그(catalog) 같은 비즈니스 정보의 양이 급속도로 증가하였다. 이를 효율적으로 처리하고자 RDF 메타데이타 프레임워크를 이용한 메타데이타의 관리 필요성이 대두되었다. RDF 메타데이타의 관리는 RDF/RDFS의 지식에 대해 제약받지 않고 웹 자원을 기술할 수 있어야 하고 메타데이타의 유효성을 보장하기 위한 환경을 지원하여야 딴다. 그러나 이를 적절히 지원할 수 있는 연구가 아직까지 미흡한 상황이다. 이를 위해 본 논문에서는 RDF/RDFS 문서를 다양한 인터페이스를 통해 생성 및 관리가 가능하며, RBF를 이용하여 기술된 메타데이타를 N-Triple로 제공함과 동시에 메타데이타의 유효성 검증이 가능하도록 하였다. The quantity of business information like to be shared enterprise information and business catalog quickly increased because of activating e-commerce. Necessary of metadata management which is using RDF was required. RDF metadata management does not have to be restricted by RDF/RDFS knowledges, has to describe web resources and has to support metadata validation. But research which supports this is not enough. In this paper we enable to create and manage RDF/RDFS document using various interfaces, change from metadata to N-Triple and verify metadata validation.
Jeong, Jae-Heon,Cho, Byoung Chul,Shim, Hyo Sup,Kim, Hye-Ryun,Lim, Sun-Min,Kim, Se Kyu,Chung, Kyung Young,Islam, S.M. Bakhtiar Ul,Song, Jae Jin,Kim, Soo-Youl,Kim, Joo Hang The Korean Academy of Medical Sciences 2013 JOURNAL OF KOREAN MEDICAL SCIENCE Vol.28 No.7
<P>Transglutaminase 2 (TG2), a cross-linking enzyme, is involved in drug resistance and in the constitutive activation of nuclear factor kappa B (NF-κB). We investigated the association of non-small cell lung cancer (NSCLC) treatment efficacy with TG2 and NF-κB expression in 120 patients: 102 with adenocarcinoma and 18 with other histologic types. All patients underwent surgery; 88 received adjuvant chemotherapy, with 28 receiving platinum-based doublet chemotherapy as first-line treatment and 29 receiving epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy. Patients' TG2 and NF-κB expression values were calculated semiquantitatively. The median TG2 value was 50 (range, 0-300) and the median NF-κB value was 20 (range, 0-240). Disease-free survival did not differ between the low- and high-TG2 groups. Among patients who received palliative platinum-based doublet chemotherapy, progression free survival (PFS) was longer in the low-TG2 group than in the high-TG2 group (11.0 vs. 7.0 months; <I>P</I>=0.330). Among those who received EGFR-TKI therapy, PFS was also longer in the low-TG2 group than in the high-TG 2 group (11.0 vs. 2.0 months; <I>P</I>=0.013). Similarly, in EGFR wild-type patients treated with EGFR-TKI, PFS was longer in patients with low TG2 expression (9.0 vs. 2.0 months; <I>P</I>=0.013). TG2 expression levels can predict PFS in patients with NSCLC treated with EGFR-TKI.</P>
Citric Acid 를 이용한 Ni / CaO-C 촉매의 제조 및 아세톤으로부터 MIBK 1단계 합성반응에의 적용
이호인,조규호,고병열 한국공업화학회 1999 응용화학 Vol.3 No.1
CaO-C catalysts were prepared by precipitating calcium acetate with citric acid for 4 hours in an aqueous solution at 80 ℃ followed by reduction at 500-100 ℃. The resultant average pore radius and BET surface area of CaO-C. CaO crystallite size, and CaO dispersion in CaO-C were about 15-25 A^˚. and 170-200 ㎡/g, 16.7 nm, and 7.4%, respectively. These values suggest that the highly dispersed CaO-C catalyst formed mainly due to the remained carbon acting as a spacer. The 4 wt% Ni/CaO-C reduced at 700 ℃ was used for one step synthesis of MIBK from acetone. 60-70% of acetone overall conversion and 70% of MIBK selectivity were obtained which are much higher than those ever reported. The DIBK selectivity was decreased drastically because the remained carbon lowered the basic strength of CaO.